An Analysis of the Efficacy of Risankizumab in Patients With Moderate-to-Severe Crohn&#39;s Disease by Disease Duration: Findings From the SEQUENCE Study

Stelara (ustekinumab) - J&J

Skyrizi (risankizumab-rzaa) - AbbVie, Boehringer Ingelheim

https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=829943&rnd=0.6451747

Laurent Peyrin-Biroulet MD PhD 1; Shomron Ben-Horin MD 2; Christina Ha MD FACG 3; Britta Siegmund MD 4; Stijn van Haaren PhD 5; Andrew Garrison PhD 6; Jameson Crowley PhD 6; Toni Anschutz NP 6; Jean-FrÃ©dÃ©ric Colombel MD 7

Aug 29, 2026